Aevis Victoria SA (AEVS) Fair Value & Analysis
Healthcare · CH · Market cap CHF 1.1B
Fair value as of: Jul 16, 2026
From 1 valuation models · updated 24 days ago
Share price +4.5% over the past month.
Below-average quality, and screening another 68% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (CHF 6.04). The favourable scenario is already priced in.
- Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (CHF 3.02 to CHF 6.04) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range CHF 11.39 – CHF 20.68 · fair‑value band CHF 3.02 – CHF 6.04 · the CHF 12.80 price screens above the CHF 4.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Aevis Victoria SA (AEVS) currently trades at CHF 12.80, while our model-based Fair Value estimate is CHF 4.05, implying the stock looks roughly 68.4% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Aevis Victoria SA generated revenue of CHF 1.0B at a net margin of -1.9%. Revenue grew 20.7% year over year. It earns a return on equity of -4.5%. Net debt stands at CHF 921M. Fundamentals as of Jul 16, 2026
Our scenario range runs from CHF 3.02 (bear case) to CHF 6.04 (bull case); at CHF 12.80, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 9% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -68%, AEVS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 36 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Aevis Victoria SA engages in the healthcare, hospitality, lifestyle, and infrastructure sectors in Switzerland. It operates through Hospitals, Hospitality, and Real Estate segments. The company operates private hospitals, hotels, radiology institutes, pharmacy, urology center, health center, day clinics, spas, patient hotels, and golf courses.
Full company description
Aevis Victoria SA engages in the healthcare, hospitality, lifestyle, and infrastructure sectors in Switzerland. It operates through Hospitals, Hospitality, and Real Estate segments. The company operates private hospitals, hotels, radiology institutes, pharmacy, urology center, health center, day clinics, spas, patient hotels, and golf courses. It also provides health management programs, lifestyle coaching and anti-aging cosmeceuticals under the Nescens brand. In addition, the company offers ambulance, life sciences related services, medical home, physiotherapy, ophthalmology, sports medicine, medical radiation, stem cells, cosmetics, parking, cleaning services, sterilization, and IT related services. Further, it owns real estate properties in the healthcare and hospitality sectors. The company was founded in 2006 and is headquartered in Fribourg, Switzerland. Aevis Victoria SA operates as a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aevis Victoria SA reported revenue of CHF 1.1B in FY2025 versus CHF 823M in FY2021, a compound +8.3%/yr. Reported net income was −CHF 20.1M in FY2025.
AEVS screens 68% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Aevis Victoria SA with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aevis Victoria SA (AEVS) overvalued or undervalued?
What is the fair value of AEVS?
What is the quality score of AEVS?
What is the revenue of Aevis Victoria SA (AEVS)?
What is the net profit margin of AEVS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Aevis Victoria SA and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.